Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer.
Ko HC, Seager RJ, Pabla S, Senosain MF, Van Roey E, Gao S, Strickland KC, Previs RA, Green MF, Cooper M, Nesline MK, Hastings SB, Amoah KA, Zhang S, Conroy JM, Jensen TJ, Eisenberg M, Caveney B, Severson EA, Ramkissoon S, Gandhi S.
Ko HC, et al. Among authors: strickland kc.
Breast Cancer (Dove Med Press). 2024 Aug 23;16:483-495. doi: 10.2147/BCTT.S476394. eCollection 2024.
Breast Cancer (Dove Med Press). 2024.
PMID: 39192887
Free PMC article.